Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
194 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Acute Pain - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Acute Pain - Pipeline Review, H2 2016', provides an overview of the Acute Pain pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Pain and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Pain - The report reviews pipeline therapeutics for Acute Pain by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Acute Pain therapeutics and enlists all their major and minor projects - The report assesses Acute Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Acute Pain Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Acute Pain - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Acute Pain Overview 9 Therapeutics Development 10 Pipeline Products for Acute Pain - Overview 10 Pipeline Products for Acute Pain - Comparative Analysis 11 Acute Pain - Therapeutics under Development by Companies 12 Acute Pain - Therapeutics under Investigation by Universities/Institutes 16 Acute Pain - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Acute Pain - Products under Development by Companies 21 Acute Pain - Products under Investigation by Universities/Institutes 25 Acute Pain - Companies Involved in Therapeutics Development 26 AcelRx Pharmaceuticals, Inc. 26 Adynxx, Inc. 27 Amorsa Therapeutics Inc. 28 AnaBios Corporation 29 Anavex Life Sciences Corp. 30 AngioChem Inc. 31 Antibe Therapeutics, Inc. 32 AskAt Inc. 33 Cara Therapeutics, Inc. 34 Centrexion Therapeutics Corp 35 Charleston Laboratories, Inc. 36 ChironWells GmbH 37 Crescita Therapeutics Inc. 38 Cytogel Pharma, LLC 39 Dompe Farmaceutici S.p.A. 40 Grunenthal GmbH 41 Iroko Pharmaceuticals, LLC 42 KemPharm, Inc. 43 KPI Therapeutics, Inc. 44 Laboratorios Del Dr. Esteve S.A. 45 Mallinckrodt Plc 46 Nanomerics Ltd 47 Nanotherapeutics, Inc. 48 Orbis Biosciences Inc 49 Orexo AB 50 Orion Oyj 51 Pacira Pharmaceuticals, Inc. 52 Phosphagenics Limited 53 Recro Pharma, Inc. 54 Scilex Pharmaceuticals, Inc. 55 Shulov Innovative Science Ltd. 56 Syntrix Biosystems, Inc. 57 Thar Pharmaceuticals, Inc. 58 Trevena, Inc. 59 Yungjin Pharm. Co., Ltd. 60 Acute Pain - Therapeutics Assessment 61 Assessment by Monotherapy Products 61 Assessment by Combination Products 62 Assessment by Target 63 Assessment by Mechanism of Action 66 Assessment by Route of Administration 69 Assessment by Molecule Type 71 Drug Profiles 73 (acetaminophen + benzhydrocodone hydrochloride) IR - Drug Profile 73 (acetaminophen + hydrocodone bitartarate) ER - Drug Profile 79 (acetaminophen + tramadol hydrochloride) SR - Drug Profile 81 (buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 82 (celecoxib + tramadol hydrochloride) - Drug Profile 83 AAT-076 - Drug Profile 85 alfentanil hydrochloride - Drug Profile 86 AMS-410 FA - Drug Profile 87 ANAVEX-1037 - Drug Profile 88 ANAVEX-1066 - Drug Profile 89 ANAVEX-1067 - Drug Profile 90 ANAVEX-1079 - Drug Profile 91 ANAVEX-1519 - Drug Profile 92 ANG-2002 - Drug Profile 93 ARX-04 - Drug Profile 94 ATB-352 - Drug Profile 99 AYX-1 - Drug Profile 100 BBI-11008 - Drug Profile 102 celecoxib - Drug Profile 103 CL-108 - Drug Profile 104 CR-4056 - Drug Profile 106 Cyt-1010 - Drug Profile 107 dexmedetomidine hydrochloride - Drug Profile 109 DF-2593A - Drug Profile 112 difelikefalin - Drug Profile 113 Drug for Acute Pain - Drug Profile 121 ECP-1014 - Drug Profile 122 ET-1 - Drug Profile 123 FY-101C - Drug Profile 124 FY-103B - Drug Profile 125 grapiprant - Drug Profile 126 HPI-201 - Drug Profile 128 HS-731 - Drug Profile 129 ibuprofen - Drug Profile 130 ibuprofen - Drug Profile 131 ibuprofen - Drug Profile 132 ketamine hydrochloride - Drug Profile 133 lidocaine hydrochloride - Drug Profile 135 meloxicam - Drug Profile 136 meloxicam - Drug Profile 139 meloxicam ER - Drug Profile 140 Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile 141 MR-309 - Drug Profile 142 NM-0127 - Drug Profile 144 oliceridine - Drug Profile 145 Omnitram - Drug Profile 150 Peptides to Target TRPV1 for Pain and Itch - Drug Profile 151 prednisone - Drug Profile 152 Prostatic Acid Phosphatase - Drug Profile 153 RO-656570 - Drug Profile 154 Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile 155 Small Molecules to Block Nav 1.7 for Pain - Drug Profile 156 Small Molecules to Block Nav 1.8 for Pain - Drug Profile 157 Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain - Drug Profile 158 T-109 - Drug Profile 159 tapentadol hydrochloride - Drug Profile 160 TRV-734 - Drug Profile 162 U-2902 - Drug Profile 164 VPX-595 - Drug Profile 166 ZEP-3 - Drug Profile 167 Acute Pain - Dormant Projects 169 Acute Pain - Discontinued Products 176 Acute Pain - Product Development Milestones 178 Featured News & Press Releases 178 Appendix 189 Methodology 189 Coverage 189 Secondary Research 189 Primary Research 189 Expert Panel Validation 189 Contact Us 189 Disclaimer 190
List of Tables
Number of Products under Development for Acute Pain, H2 2016 14 Number of Products under Development for Acute Pain - Comparative Analysis, H2 2016 15 Number of Products under Development by Companies, H2 2016 17 Number of Products under Development by Companies, H2 2016 (Contd..1) 18 Number of Products under Development by Companies, H2 2016 (Contd..2) 19 Number of Products under Investigation by Universities/Institutes, H2 2016 20 Comparative Analysis by Late Stage Development, H2 2016 21 Comparative Analysis by Clinical Stage Development, H2 2016 22 Comparative Analysis by Early Stage Development, H2 2016 23 Comparative Analysis by Unknown Stage Development, H2 2016 24 Products under Development by Companies, H2 2016 25 Products under Development by Companies, H2 2016 (Contd..1) 26 Products under Development by Companies, H2 2016 (Contd..2) 27 Products under Development by Companies, H2 2016 (Contd..3) 28 Products under Investigation by Universities/Institutes, H2 2016 29 Acute Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H2 2016 30 Acute Pain - Pipeline by Adynxx, Inc., H2 2016 31 Acute Pain - Pipeline by Amorsa Therapeutics Inc., H2 2016 32 Acute Pain - Pipeline by AnaBios Corporation, H2 2016 33 Acute Pain - Pipeline by Anavex Life Sciences Corp., H2 2016 34 Acute Pain - Pipeline by AngioChem Inc., H2 2016 35 Acute Pain - Pipeline by Antibe Therapeutics, Inc., H2 2016 36 Acute Pain - Pipeline by AskAt Inc., H2 2016 37 Acute Pain - Pipeline by Cara Therapeutics, Inc., H2 2016 38 Acute Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016 39 Acute Pain - Pipeline by Charleston Laboratories, Inc., H2 2016 40 Acute Pain - Pipeline by ChironWells GmbH, H2 2016 41 Acute Pain - Pipeline by Crescita Therapeutics Inc., H2 2016 42 Acute Pain - Pipeline by Cytogel Pharma, LLC, H2 2016 43 Acute Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 44 Acute Pain - Pipeline by Grunenthal GmbH, H2 2016 45 Acute Pain - Pipeline by Iroko Pharmaceuticals, LLC, H2 2016 46 Acute Pain - Pipeline by KemPharm, Inc., H2 2016 47 Acute Pain - Pipeline by KPI Therapeutics, Inc., H2 2016 48 Acute Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016 49 Acute Pain - Pipeline by Mallinckrodt Plc, H2 2016 50 Acute Pain - Pipeline by Nanomerics Ltd, H2 2016 51 Acute Pain - Pipeline by Nanotherapeutics, Inc., H2 2016 52 Acute Pain - Pipeline by Orbis Biosciences Inc, H2 2016 53 Acute Pain - Pipeline by Orexo AB, H2 2016 54 Acute Pain - Pipeline by Orion Oyj, H2 2016 55 Acute Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016 56 Acute Pain - Pipeline by Phosphagenics Limited, H2 2016 57 Acute Pain - Pipeline by Recro Pharma, Inc., H2 2016 58 Acute Pain - Pipeline by Scilex Pharmaceuticals, Inc., H2 2016 59 Acute Pain - Pipeline by Shulov Innovative Science Ltd., H2 2016 60 Acute Pain - Pipeline by Syntrix Biosystems, Inc., H2 2016 61 Acute Pain - Pipeline by Thar Pharmaceuticals, Inc., H2 2016 62 Acute Pain - Pipeline by Trevena, Inc., H2 2016 63 Acute Pain - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016 64 Assessment by Monotherapy Products, H2 2016 65 Assessment by Combination Products, H2 2016 66 Number of Products by Stage and Target, H2 2016 68 Number of Products by Stage and Mechanism of Action, H2 2016 71 Number of Products by Stage and Route of Administration, H2 2016 74 Number of Products by Stage and Molecule Type, H2 2016 76 Acute Pain - Dormant Projects, H2 2016 173 Acute Pain - Dormant Projects (Contd..1), H2 2016 174 Acute Pain - Dormant Projects (Contd..2), H2 2016 175 Acute Pain - Dormant Projects (Contd..3), H2 2016 176 Acute Pain - Dormant Projects (Contd..4), H2 2016 177 Acute Pain - Dormant Projects (Contd..5), H2 2016 178 Acute Pain - Dormant Projects (Contd..6), H2 2016 179 Acute Pain - Discontinued Products, H2 2016 180 Acute Pain - Discontinued Products (Contd..1), H2 2016 181
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
